A5056730917- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Asthma and respiratory diseases
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- Gastric Cancer Management and Outcomes
- IL-33, ST2, and ILC Pathways
- Colorectal and Anal Carcinomas
- Pediatric health and respiratory diseases
- Nutrition and Health in Aging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammatory Biomarkers in Disease Prognosis
- Neuroendocrine Tumor Research Advances
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Allergic Rhinitis and Sensitization
- Palliative Care and End-of-Life Issues
- Eosinophilic Esophagitis
- Immune Cell Function and Interaction
- Cancer therapeutics and mechanisms
- Respiratory and Cough-Related Research
- Circular RNAs in diseases
Kyoto Prefectural University of Medicine
2017-2025
Otsu Municipal Hospital
2022
City Hospital
2022
University of Tsukuba
2011-2021
Zhongshan Hospital
2019
Fudan University
2019
Ibarakihigashi National Hospital
2004
National Hospital Organization
2004
Abstract Purpose: Currently, an optimal therapeutic strategy comprising molecularly targeted agents for treating EGFR-mutated non–small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib is not available. Therefore, the initial intervention crucial prolonged survival of these patients. The activation anexelekto (AXL) signaling known be associated intrinsic and EGFR tyrosine kinase inhibitors (EGFR-TKIs). In this study, we investigated best combat AXL-induced tolerance...
Abstract Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients EGFR ‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation NSCLC mutations who exhibit clinical outcomes that require treatment immune checkpoint (ICIs). Therefore, identify eligible cases treat ICIs, we retrospectively analyzed correlation between features and efficacy ICIs mutations. Patients Methods...
Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary an indicator of postoperative recurrence. We hypothesized there correlation between the effect immune checkpoint inhibitors (ICIs) and sarcopenia. retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated ICIs February 2016 April 2018. Patients divided into two groups according change rate psoas major area...
Background: Cancer immunotherapy is being developed as a promising alternative for advanced non-small cell lung cancer (NSCLC). However, novel biomarkers are required to select patients that will benefit from treatment with immune checkpoint inhibitors (ICIs) long period of time. The gut microbiome expected be biomarker ICI response owing the regulation status within host.
Little is known regarding the effectiveness and tolerability of immune checkpoint inhibitor (ICI) rechallenge after disease progression following initial ICI treatments. To identify eligible patients for rechallenge, we retrospectively analyzed relationship between clinical profiles effect in with non-small cell lung cancer (NSCLC). We enrolled 35 NSCLC at six different institutions who were retreated ICIs discontinued treatments due to progression. Cox proportional hazards models used...
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated significantly better survival outcomes than alone in patients advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The nutritional index (PNI) (LIPI) biomarkers inhibitor (ICI) monotherapy or chemotherapies. Thus, we aimed to examine whether these factors could also be We retrospectively examined 237 NSCLC treated In...
Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of on chemoimmunotherapy unclear. We investigated therapeutic outcomes non-small cell lung (NSCLC). retrospectively analyzed patients' medical records with NSCLC who received in 12 institutions Japan between January and November 2019. defined as weight loss exceeding 5% total body or mass index < 20 kg/m2 more than 2% within 6 months before initiation,...
Abstract Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have shown dramatic efficacy in patients with ALK-rearranged lung cancer; however, complete response these is rare. Here, we investigated the molecular mechanisms underlying emergence and maintenance of drug-tolerant cells cancer. Cell based-assays demonstrated that HER3 activation mesenchymal-to-epithelial transition, mediated through ZEB1 proteins, help maintain cell survival induce ALK-TKI-tolerant cells. Compared...
Abstract: Few studies have investigated the significance of decreased FEV 1 in non-COPD, nonasthmatic healthy subjects. We hypothesized that a lower these subjects is potential marker an increased susceptibility to obstructive lung disease such as asthma and COPD. This was cross-sectional analysis 1505 Japanese adults. divided population adults with no respiratory diseases whose /FVC ratio ≥70% (n = 1369) into 2 groups according their prebronchodilator (% predicted) measurements:<80% 217)...
Reports on the use of cryobiopsy (CB) for lung cancer diagnosis are limited. The aims present study were to evaluate safety and usefulness CB using radial endobronchial ultrasonography, without a guide sheath, peripheral pulmonary lesions determine utility stamp cytology, an on-site diagnostic technique determining tumor inclusion in samples. We retrospectively analyzed data 35 patients (36 lesions) with suspected who underwent between August 2017 February 2019 at our medical facility....
Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Elevated programmed death-ligand 1 (PD-L1) expression in tumors was reported negative predictive outcomes first- or second-generation EGFR-TKIs.We prospectively assessed...
Abstract: Recently, several genes and genetic loci associated with both asthma chronic obstructive pulmonary disease (COPD) have been described as common susceptibility factors for the two diseases. In complex diseases such COPD, a large number of molecular cellular components may interact through networks involving gene–gene gene–environment interactions. We sought to understand functional regulatory pathways that play central roles in pathobiology COPD overlap between these pathways....
Abstract Cancer immunotherapy, including atezolizumab monotherapy, is a promising alternative strategy for patients with advanced non-small-cell lung cancer (NSCLC). Several inflammatory indices have been reported as potential biomarkers regarding the effectiveness of various treatments. This study aimed to analyze efficacy monotherapy using baseline markers in NSCLC patients. We retrospectively enrolled 81 who received at six different medical institutions Japan. The Cox proportional...
The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with good clinical outcomes. However, effects remain unknown. In this study, we investigated association between irAEs caused by and efficacy patients NSCLC.We retrospectively analyzed data NSCLC, who received a at six institutions Japan January 2019...
Recent studies have demonstrated that a coding SNP (rs6967330, Cys529→Tyr) in cadherin-related family member 3 (CDHR3), which was previously associated with wheezing illness and hospitalizations infancy, could support efficient human rhinovirus C (RV-C) entry replication. Here, we sought to examine the genetic contribution of this variant development adult asthma.We performed candidate gene case-control association study 2 independent Japanese populations (a total 3366 adults). The odds...
Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, therapy docetaxel (Doc) ramucirumab (Ram) was considered one standard treatments advanced or relapsed NSCLC patients. However, little is known about therapeutic responders this among previously treated present study, we aimed identify predictive...
Interstitial lung disease (ILD) is a serious complication of connective tissue diseases (CTDs). The heterogeneity ILDs reflects differences in pathogenesis among diseases. This study aimed to clarify the characteristics CTD-ILDs via detailed analysis bronchoalveolar lavage fluid (BALF) and blood immune cells. BALF samples were collected from 39 Japanese patients with newly diagnosed ILD: five Sjögren's syndrome (SS), eight dermatomyositis (DM), six rheumatoid arthritis (RA), systemic...
Abstract Lessons Learned Non-small-cell lung cancer (NSCLC) represents 85% of in elderly patients. In the present study performed 36 subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement objective response rate, which was comparable to those nonelderly population. Osimertinib appears be an effective and safe treatment option patients advanced NSCLC EGFR mutation; further research larger scale...